RU2650962C2 - Способы лечения нейтропении с применением ретиноидных агонистов - Google Patents

Способы лечения нейтропении с применением ретиноидных агонистов Download PDF

Info

Publication number
RU2650962C2
RU2650962C2 RU2014153988A RU2014153988A RU2650962C2 RU 2650962 C2 RU2650962 C2 RU 2650962C2 RU 2014153988 A RU2014153988 A RU 2014153988A RU 2014153988 A RU2014153988 A RU 2014153988A RU 2650962 C2 RU2650962 C2 RU 2650962C2
Authority
RU
Russia
Prior art keywords
day
neutropenia
csf
tamibarotene
neutrophils
Prior art date
Application number
RU2014153988A
Other languages
English (en)
Russian (ru)
Other versions
RU2014153988A (ru
Inventor
Линтао ВУ
Original Assignee
Чилдрен'З Хоспитал Лос Анджелес
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чилдрен'З Хоспитал Лос Анджелес filed Critical Чилдрен'З Хоспитал Лос Анджелес
Publication of RU2014153988A publication Critical patent/RU2014153988A/ru
Application granted granted Critical
Publication of RU2650962C2 publication Critical patent/RU2650962C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014153988A 2012-06-07 2013-06-07 Способы лечения нейтропении с применением ретиноидных агонистов RU2650962C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
RU2014153988A RU2014153988A (ru) 2016-07-27
RU2650962C2 true RU2650962C2 (ru) 2018-04-18

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014153988A RU2650962C2 (ru) 2012-06-07 2013-06-07 Способы лечения нейтропении с применением ретиноидных агонистов

Country Status (13)

Country Link
US (1) US11116738B2 (https=)
EP (1) EP2858636B1 (https=)
JP (1) JP6295249B2 (https=)
KR (1) KR102083046B1 (https=)
CN (1) CN104519879B (https=)
AU (1) AU2013270674B2 (https=)
BR (1) BR112014030279A2 (https=)
CA (1) CA2874850A1 (https=)
ES (1) ES2691493T3 (https=)
MX (1) MX365321B (https=)
NZ (1) NZ702415A (https=)
RU (1) RU2650962C2 (https=)
WO (1) WO2013185105A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
MX2016010699A (es) * 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
PL3277272T3 (pl) 2015-03-31 2022-01-24 Syros Pharmaceuticals, Inc. Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
EP3743722A4 (en) * 2018-01-26 2022-03-02 Agency for Science, Technology and Research NEUTROPHIL SUBTYPES
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98114840A (ru) * 1995-12-29 2001-06-27 Аллерген Сэйлз, Инк. СПОСОБЫ ЛЕЧЕНИЯ ПРИ ПОМОЩИ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ СПЕЦИФИЧНОЙ ИЛИ СЕЛЕКТИВНОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ РЕТИНОВОЙ КИСЛОТЫ (PPKα)
RU2191009C2 (ru) * 1995-12-29 2002-10-20 Аллерген Сэйлз, Инк. СПОСОБЫ ЛЕЧЕНИЯ ПРИ ПОМОЩИ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ СПЕЦИФИЧНОЙ ИЛИ СЕЛЕКТИВНОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ РЕТИНОВОЙ КИСЛОТЫ (PPKα)
WO2006010503A2 (en) * 2004-07-29 2006-02-02 Werner Bollag Rxr antagonists in the treatment of inflammatory diseases
US20090176862A1 (en) * 2006-05-16 2009-07-09 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
EP0957918A1 (en) * 1996-12-19 1999-11-24 American Cyanamid Company Method of treating or inhibiting neutropenia
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
KR20060018851A (ko) 2003-05-16 2006-03-02 교와 핫꼬 고교 가부시끼가이샤 조직 파괴를 수반하는 질환의 예방 및/또는 치료제
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
ATE476981T1 (de) 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
EP2143428B1 (en) * 2007-03-30 2015-11-04 TMRC Co., Ltd. Tamibarotene capsule preparation
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
CN102612371B (zh) 2009-10-19 2014-03-19 莱拉营养食品有限公司 含有多聚乙酰的提取物，分馏物和混合物及它们的应用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA2826386C (en) 2011-02-08 2020-04-28 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
JP6242868B2 (ja) * 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98114840A (ru) * 1995-12-29 2001-06-27 Аллерген Сэйлз, Инк. СПОСОБЫ ЛЕЧЕНИЯ ПРИ ПОМОЩИ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ СПЕЦИФИЧНОЙ ИЛИ СЕЛЕКТИВНОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ РЕТИНОВОЙ КИСЛОТЫ (PPKα)
RU2191009C2 (ru) * 1995-12-29 2002-10-20 Аллерген Сэйлз, Инк. СПОСОБЫ ЛЕЧЕНИЯ ПРИ ПОМОЩИ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ СПЕЦИФИЧНОЙ ИЛИ СЕЛЕКТИВНОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ РЕТИНОВОЙ КИСЛОТЫ (PPKα)
WO2006010503A2 (en) * 2004-07-29 2006-02-02 Werner Bollag Rxr antagonists in the treatment of inflammatory diseases
US20090176862A1 (en) * 2006-05-16 2009-07-09 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЧУБЕНКО А.В. Анализ приоритетных исследований в области новых лекарственных средств за рубежом. Провизор 2003, вып.1, найдено 28.02.2017 из Интернет: http://www.provisor.com.ua/archive/2003/N1/art_06.pgp. *

Also Published As

Publication number Publication date
ES2691493T3 (es) 2018-11-27
JP2015523346A (ja) 2015-08-13
AU2013270674A1 (en) 2014-12-18
JP6295249B2 (ja) 2018-03-14
AU2013270674B2 (en) 2017-12-07
KR102083046B1 (ko) 2020-02-28
WO2013185105A1 (en) 2013-12-12
HK1208630A1 (en) 2016-03-11
US11116738B2 (en) 2021-09-14
MX365321B (es) 2019-05-29
EP2858636A1 (en) 2015-04-15
US20150164836A1 (en) 2015-06-18
EP2858636A4 (en) 2016-06-01
CN104519879B (zh) 2018-10-02
BR112014030279A2 (pt) 2017-09-12
KR20150035983A (ko) 2015-04-07
CA2874850A1 (en) 2013-12-12
RU2014153988A (ru) 2016-07-27
MX2014014930A (es) 2015-07-06
CN104519879A (zh) 2015-04-15
NZ702415A (en) 2016-04-29
EP2858636B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
RU2650962C2 (ru) Способы лечения нейтропении с применением ретиноидных агонистов
Stoye et al. Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice
JP6353073B2 (ja) 細胞回復のための組成物並びにその作製及び使用方法
AU2022228188A1 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
US20220241240A1 (en) Agents and methods for increasing stem cell function
IL268129B1 (en) Preparations and methods for controlling the activation and function of natural killer cells (NK cells)
US20260048083A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
Fernandez-Botran et al. Advanced methods in cellular immunology
CN117122685A (zh) Rage抑制剂在制备预防或治疗听力损伤的产品中的用途
WO2010054393A1 (en) Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
JP6000206B2 (ja) 抗アレルギー用経口組成物
Soltys et al. Isolation of bovine neutrophils with biomagnetic beads: comparison with standard Percoll density gradient isolation methods
JP2022537336A (ja) 制御性ｃｄ４＋ ｔ細胞を生成するためのスフィンゴ脂質
JP2025520155A (ja) ガンマデルタｔ細胞による老化細胞の標的除去
CN117159525A (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
KR101059724B1 (ko) 천연 킬러 세포를 증식시키는 작용을 갖는 물질의 스크리닝방법
US20240228966A1 (en) Urolithin for increasing stem cell function
Alatshan Retinoic acid modulates nod-like receptor-mediated responses in human macrophages
長澤貴宏 Studies on Phagocytosis and Immune-related Functions of Nucleated Thrombocytes in Early Vertebrates
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK1256917B (en) Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200608